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• Meningitis and encephalitis are central nervous 
system (CNS) infectious diseases associated with 
significant morbidity and mortality in adult populations.
• Traditional approaches of culture and pathogen-
specific polymerase chain reaction (PCR) tests are 
limited by slow turnaround time and low diagnostic 
yield.
• The FilmArray Meningitis and Encephalitis (M/E) panel 
is a multiplex PCR test targeting a combination of 14 
viruses, bacteria, and yeasts. 
• The M/E panel was first introduced at LVHN in 
February, 2016.
• Time to diagnosis decreased in the post-
intervention group for all pathogens included on the 
M/E panel.
• The post-intervention group had a reduced time 
from antibiotic initiation to discontinuation (70.0 h vs 
81.7 h) and reduced antibiotic days of therapy (2.9 
d vs 3.4 d) for negative CSF results
• The post-intervention group had an overall 
decreased mean time to targeted therapy (27.7 h 
vs. 32.9 h) and reduced mean time to diagnosis 
(21.2 h vs. 39.1 h) for positive CSF results.
• The post-intervention group had a reduced average 
number of CSF tests (3.6 vs. 4.7).
• Notably, this translated into an increase in the 
average patient charge: $1,339.79 vs. $1,458.45, 
but a decrease in the average supply cost ($434.26 
vs $314.29) in the post-intervention group.
This study aims to determine how the M/E panel 
affects clinical outcomes including: time to 
diagnosis, appropriate antibiotic deescalation, days 
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Methods
Retrospective analysis of patients with CSF culture 
from 2/23/2015 to 2/22/2016 (Pre-Intervention) and 
M/E panel and CSF culture from 2/23/2016 to 
2/22/2017 (Post-Intervention). 
Review EMR for: demographics, length of stay, type 
of CSF studies, CSF collection date and time, CSF 
result date and time, antibiotics administered, 
antibiotic initiation and discontinuation date and time. 
Perform descriptive statistics to compare the pre and 
post-intervention groups regarding: time to 










81.7 (85.5) 70.0 (93.2)
Mean Days of 
Therapy (SD)
3.4 (3.6) 2.9 (3.9)
Mean # CSF Tests 
Ordered (Range)
4.7 (1-13) 3.8 (2-13)
Mean Length of Stay 
Days (Range)
7.9 (1-33) 9.5 (2-57)
Key: ICU, Intensive Care Unit; CSF, cerebrospinal fluid.





Mean Time to 
Targeted Antibiotic 
(SD)
32.9 (25.9) 27.7 (32.2)
Mean Time to 
Diagnosis in Hours 
(SD)
39.1 (40.3) 21.2 (39.0)
Mean # CSF Tests 
Ordered (Range)
5.0 (2-10) 2.9 (2-5)
Mean Length of 
Stay Days (Range)
7.6 (1-28) 9.0 (3-52)
• The implementation of the M/E panel has resulted 
in improved time to diagnosis, time to antibiotic 
deescalation for negative CSF tests and time to 
targeted antibiotic therapy for positive CSF test 
results
• Future research using a larger sample size is 
needed to determine if there is a change in 
outcomes data including: length of stay, ICU stay, 
and mortality.
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r) Figure 2. Time from Antibiotic Initiation to Targeted Therapy for Positive CSF Test Results
Pathogen
*M/EP does not include Lyme disease nor other bacterial etiologies


































**Standard error bars and data points included. 
